Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Blood Cancer Journal (86)
Leukemia (85)
Bone Marrow Transplantation (26)
Nature Communications (6)
Oncogene (3)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (157)
Correspondence (28)
Reviews (16)
Amendments and Corrections (14)
Editorial (3)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Biomarkers
Cancer
Cell biology
Diseases
Drug discovery
Gastroenterology
Genetics
Health care
Immunology
Medical research
Microbiology
Oncology
Pathogenesis
Risk factors
Signs and symptoms
Stem cells
Systems biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 218 results

Advanced filters: Author: Shaji Kumar Clear advanced filters

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019

Chronic care manages long-term, progressive conditions, while acute care handles short-term ones. Here, authors show chronic conditions account for most of the global health burden, with 68% of DALYs and 93% of YLDs attributed to chronic care needs.

Cecilia Anza-Ramirez
J. Jaime Miranda
Yves Miel H. Zuniga
ResearchOpen Access07 May 2025
Nature Communications

Volume: 16, P: 1-36
Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia

Arwa Bohra
Rafla Hassan
Shaji Kumar
Research26 May 2025
Leukemia

P: 1-3
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma

Saurabh Zanwar
Dragan Jevremovic
Shaji Kumar
ResearchOpen Access18 Feb 2025
Blood Cancer Journal

Volume: 15, P: 1-6
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Sham Mailankody
Jeffrey V. Matous
Shaji K. Kumar
Amendments and Corrections17 Mar 2023
Nature Medicine

Volume: 29, P: 3271
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget
Daniel Penaherrera
Jonathan J. Keats
Amendments and CorrectionsOpen Access09 Jun 2025
Nature Genetics

P: 1
Capillary leak phenotype as a major cause of death in patients with POEMS syndrome

Kenzie Lee
Taxiarchis Kourelis
Angela Dispenzieri
ResearchOpen Access16 Dec 2024
Leukemia

Volume: 39, P: 703-709
Correction: Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients

Elad Ziv
Eric Dean
Celine Vachon
Amendments and Corrections09 Dec 2015
Nature Communications

Volume: 6, P: 1
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

Radhika Bansal
Mizba Baksh
Yi Lin
ResearchOpen Access05 Apr 2023
Blood Cancer Journal

Volume: 13, P: 1-5
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience

Sarah Goldman-Mazur
Alissa Visram
Shaji K. Kumar
ResearchOpen Access06 Dec 2022
Blood Cancer Journal

Volume: 12, P: 1-6
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma

Charalampos Charalampous
Utkarsh Goel
Shaji Kumar
ResearchOpen Access06 Oct 2022
Bone Marrow Transplantation

Volume: 58, P: 46-53
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702

Rahul Banerjee
Amber R. Fritz
Marcelo C. Pasquini
Research24 Feb 2025
Leukemia

Volume: 39, P: 1001-1004
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

Abiola Bolarinwa
Madhu Nagaraj
Shaji Kumar
ResearchOpen Access04 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-7
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies

Shaji Kumar
Dirk R. Larson
S. Vincent Rajkumar
ResearchOpen Access17 May 2019
Blood Cancer Journal

Volume: 9, P: 1-6
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma

Gaurav Goyal
S. Vincent Rajkumar
Shaji K. Kumar
Research20 Feb 2019
Leukemia

Volume: 33, P: 1273-1277
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

In an interim phase 1 trial analysis, escalating doses of off-the-shelf allogeneic anti-BCMA CAR T cells, in combination with an anti-CD52 antibody-containing lymphodepletion regimen, were feasible to administer and exhibited an encouraging safety profile in patients with relapsed or refractory multiple myeloma

Sham Mailankody
Jeffrey V. Matous
Shaji K. Kumar
Research23 Jan 2023
Nature Medicine

Volume: 29, P: 422-429
The ratio of brain to liver glucose activity and disease activity in multiple myeloma

Sarah Dingli
Paul Rothweiler
David Dingli
ResearchOpen Access07 May 2025
Blood Cancer Journal

Volume: 15, P: 1-9
Drug Insight: thalidomide as a treatment for multiple myeloma

Understanding the tumor microenvironment and bone marrow interactions for multiple myeloma is crucial for the development of new therapies aimed at circumventing resistance to conventional therapy. Kumar and Anderson discuss how the development of thalidomide and its immunomodulatory derivatives are a milestone in the treatment of this disease, and how assessment of these agents in model systems has shown great promise in the clinic, thereby paving the way for the development of even more effective therapies.

Shaji Kumar
Kenneth C Anderson
Reviews01 May 2005
Nature Clinical Practice Oncology

Volume: 2, P: 262-270
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Thierry Facon
Philippe Moreau
Shaji K. Kumar
ResearchOpen Access27 Feb 2025
Leukemia

Volume: 39, P: 942-950
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

Utkarsh Goel
Charalampos Charalampous
Shaji K. Kumar
ResearchOpen Access26 Mar 2024
Blood Cancer Journal

Volume: 14, P: 1-6
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group

Xinyan Lu
Erica F. Andersen
Linda B. Baughn
ReviewsOpen Access18 Jun 2025
Blood Cancer Journal

Volume: 15, P: 1-10
Mode of progression in smoldering multiple myeloma: a study of 406 patients

Nadine H. Abdallah
Arjun Lakshman
S. Vincent Rajkumar
ResearchOpen Access17 Jan 2024
Blood Cancer Journal

Volume: 14, P: 1-7
Molecular signatures of multiple myeloma progression through single cell RNA-Seq

Jin Sung Jang
Ying Li
Jin Jen
ResearchOpen Access03 Jan 2019
Blood Cancer Journal

Volume: 9, P: 1-10
Multiple myeloma

Multiple myeloma — a malignancy of terminally differentiated plasma cells — is the second most common haematological malignancy. This Primer by Kumar et al. highlights the mechanisms and epidemiology of multiple myeloma, and describes how updates to the diagnostic criteria have impacted patient management.

Shaji K. Kumar
Vincent Rajkumar
Kenneth C. Anderson
Reviews20 Jul 2017
Nature Reviews Disease Primers

Volume: 3, P: 1-20
Risk of lymphoid malignancy associated with cancer predisposition genes

Nicholas J. Boddicker
Raphael Mwangi
James R. Cerhan
ResearchOpen Access19 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-9
Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma

Sarah Dingli
Paul Rothweiler
David Dingli
ResearchOpen Access05 Mar 2025
Leukemia

Volume: 39, P: 1005-1008
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

Walker M. Schmidt
Nirosha D. Perera
Morie A. Gertz
ResearchOpen Access18 Aug 2023
Blood Cancer Journal

Volume: 13, P: 1-8
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients

Multiple myeloma is an incurable blood cancer with family history being a strong contributing risk factor. Here Ziv et al.perform a genome-wide association study for genetic variation associated with myeloma survival, identifying FOPNL variants associated with worse clinical outcomes.

Elad Ziv
Eric Dean
Celine Vachon
Research22 Jul 2015
Nature Communications

Volume: 6, P: 1-9
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance

Alexander J. Ryu
Shaji Kumar
Thomas C. Kingsley
ResearchOpen Access17 Feb 2023
Blood Cancer Journal

Volume: 13, P: 1-6
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Vaccination is effective in protecting from COVID-19. Here the authors report immune responses and breakthrough infections in twice-vaccinated patients receiving anti-TNF treatments for inflammatory bowel disease, and find dampened vaccine responses that implicate the need of adapted vaccination schedules for these patients.

Simeng Lin
Nicholas A. Kennedy
Jeannie Bishop
ResearchOpen Access16 Mar 2022
Nature Communications

Volume: 13, P: 1-14
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

Moritz Binder
Bharat Nandakumar
Shaji K. Kumar
Research26 Oct 2021
Leukemia

Volume: 36, P: 801-808
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant

Dhauna Karam
Morie Gertz
Shaji Kumar
Research16 Mar 2022
Bone Marrow Transplantation

Volume: 57, P: 803-809
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis

Alissa Visram
S. Vincent Rajkumar
Shaji Kumar
ResearchOpen Access26 Nov 2021
Blood Cancer Journal

Volume: 11, P: 1-8
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota

Geffen Kleinstern
Dirk R. Larson
Celine M. Vachon
ResearchOpen Access19 Apr 2022
Blood Cancer Journal

Volume: 12, P: 1-7
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

Abdullah S. Al Saleh
Mohammad S. Ebraheem
Morie A. Gertz
ResearchOpen Access11 Apr 2022
Blood Cancer Journal

Volume: 12, P: 1-6
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Longitudinal genomic and transcriptomic profiling of 1,143 patients with multiple myeloma by the Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study yields an improved copy number and gene expression subtype scheme, most notably a high-risk proliferative subtype associated with complete loss of RB1 or MAX.

Sheri Skerget
Daniel Penaherrera
Jonathan J. Keats
ResearchOpen Access19 Aug 2024
Nature Genetics

Volume: 56, P: 1878-1889
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents

Iuliana Vaxman
Alissa Visram
Morie A. Gertz
Research04 Dec 2020
Bone Marrow Transplantation

Volume: 56, P: 1144-1150
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

David L. Murray
Noemi Puig
Brian Durie
ResearchOpen Access01 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-6
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma

Ashley Paquin
Alissa Visram
S. Vincent Rajkumar
ResearchOpen Access28 Aug 2020
Blood Cancer Journal

Volume: 10, P: 1-7
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis

Iuliana Vaxman
M. Hasib Sidiqi
Morie Gertz
Research18 Nov 2020
Bone Marrow Transplantation

Volume: 56, P: 928-935
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

Nadine Abdallah
Surbhi Sidana
Shaji Kumar
Research09 Jun 2020
Bone Marrow Transplantation

Volume: 55, P: 1297-1304
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)

Li Pang
S. Vincent Rajkumar
Shaji Kumar
ResearchOpen Access01 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-8
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients

Patrick W. Mellors
Surendra Dasari
Angela Dispenzieri
ResearchOpen Access04 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-9
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma

Praful Ravi
Shaji K. Kumar
S. Vincent Rajkumar
ResearchOpen Access15 Nov 2018
Blood Cancer Journal

Volume: 8, P: 1-6
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Eli Muchtar
Morie A. Gertz
Angela Dispenzieri
Research22 Nov 2019
Leukemia

Volume: 34, P: 1135-1143
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma

Kevin C. Miller
Morie A. Gertz
Shaji K. Kumar
Research16 Aug 2018
Bone Marrow Transplantation

Volume: 54, P: 587-594
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Surbhi Sidana
Nidhi Tandon
Shaji K. Kumar
Research21 Dec 2017
Bone Marrow Transplantation

Volume: 53, P: 326-333
Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Gaurav Goyal
Adam C. Bartley
Wilson I. Gonsalves
Research21 Mar 2018
Leukemia

Volume: 32, P: 1414-1420
Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant

Abdullah S. Al Saleh
M. Hasib Sidiqi
Morie A. Gertz
Research01 May 2020
Bone Marrow Transplantation

Volume: 55, P: 2132-2137
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

Ashley R. Paquin
Shaji K. Kumar
S. Vincent Rajkumar
ResearchOpen Access11 Dec 2018
Blood Cancer Journal

Volume: 8, P: 1-7
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response

M Hasib Sidiqi
Mohammed A. Aljama
Morie A. Gertz
Research07 Aug 2018
Bone Marrow Transplantation

Volume: 54, P: 442-447

Previous page
page 1
page 2
page 3
…
page 5
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Italy
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2025 Springer Nature Limited